Laboratory and Sample Management

Best Practices for Clinical Sample Collection in Regulatory-Compliant Trials

Posted on digi By digi

Clinical sample collection is one of the most critical operations in a clinical trial. Improper sample collection practices can lead to preanalytical errors, invalid assay results, or even regulatory non-compliance. Regulatory agencies such as the FDA, EMA, and PMDA emphasize the importance of well-documented and standardized Sample Collection Standard Operating Procedures (SOPs) to ensure data integrity and subject safety.

Click to read the full article.

Laboratory and Sample Management, Sample Collection SOPs

Achieving Sample Collection Kits and Logistics Under FDA/EMA Oversight

Posted on digi By digi

Effective management of clinical trial sample collection kits and associated logistics is a critical element of compliance, especially in global studies under FDA and EMA oversight. These kits are the primary tools enabling the standardized and protocol-aligned collection, labeling, and shipment of clinical biospecimens such as blood, plasma, serum, urine, or tumor tissue. A failure in kit accuracy, delivery, or tracking can result in sample loss, data invalidation, or regulatory findings.

Click to read the full article.

Laboratory and Sample Management, Sample Collection SOPs

How to Achieve Temperature Control Requirements During Clinical Sample Collection

Posted on digi By digi

Temperature control during clinical sample collection is not just a technical specification—it is a regulatory imperative. Improper temperature handling can lead to sample degradation, compromised data quality, and non-compliance findings during FDA or EMA inspections. Whether storing whole blood, plasma, serum, RNA, or PBMCs, clinical trial sponsors must implement validated procedures and equipment to maintain biospecimen integrity from collection to processing.

Click to read the full article.

Laboratory and Sample Management, Sample Collection SOPs

Training Site Staff on Sample Handling: Lessons from Global Audits

Posted on digi By digi

Effective training on clinical sample handling is a cornerstone of inspection readiness and biospecimen integrity. Regulatory inspections by the FDA, EMA, and MHRA frequently highlight deficiencies in sample management, often attributable to inadequate or inconsistent training of site staff. Improper labeling, temperature excursions, and documentation errors are common non-compliance triggers.

Click to read the full article.

Laboratory and Sample Management, Sample Collection SOPs

FDA-Ready Guide – Labeling Standards for Clinical Samples

Posted on digi By digi

Accurate labeling of clinical samples is essential for ensuring traceability, subject confidentiality, and regulatory compliance. Regulatory authorities such as the FDA and EMA routinely cite mislabeling, incomplete identifiers, or illegible sample labels as significant compliance risks. The ICH E6(R2) and FDA 21 CFR Part 58 both emphasize the need for unique identification and traceable sample chains.

Click to read the full article.

Laboratory and Sample Management, Sample Collection SOPs

Consent Requirements for Sample Use – CAPA Solutions

Posted on digi By digi

The use of clinical samples for primary and secondary research hinges upon proper informed consent. Regulators such as the FDA, EMA, and ICH-GCP mandate that participants be fully informed about how their biospecimens will be used, stored, shared, or discarded. Any deviation from these expectations can result in findings related to subject rights violations, protocol non-compliance, or ethical breaches.

Click to read the full article.

Laboratory and Sample Management, Sample Collection SOPs

Sample Mislabeling: Prevention Strategies with Risk-Based Oversight

Posted on digi By digi

Sample mislabeling in clinical trials can result in compromised data integrity, participant risk, protocol deviations, and regulatory inspection findings. Regulatory bodies such as the FDA, EMA, and MHRA consider incorrect, incomplete, or missing sample identifiers as serious non-compliances that threaten subject protection and trial validity.

Click to read the full article.

Laboratory and Sample Management, Sample Collection SOPs

Inspection Readiness Playbook – Handling Hazardous Biological Samples

Posted on digi By digi

Clinical trials involving infectious diseases, gene therapy, or immune-modulating therapies often require collection and transport of hazardous biological samples such as blood, sputum, cerebrospinal fluid, or genetically modified organisms (GMOs). Mismanagement of such samples can result in biohazard exposure, protocol deviations, and regulatory non-compliance.

Click to read the full article.

Laboratory and Sample Management, Sample Collection SOPs

Time-Sensitive Sample Handling Procedures – Best Practices for FDA & EMA

Posted on digi By digi

In clinical trials, certain biological samples—such as those used for pharmacokinetic (PK), biomarker, hematology, or genetic analyses—have limited stability and must be processed or transported within defined timeframes to maintain scientific validity. Deviations in these timelines are a common source of protocol deviations and regulatory non-compliance during inspections.

Click to read the full article.

Laboratory and Sample Management, Sample Collection SOPs

How to Achieve GCP Requirements for Sample Documentation with FDA/EMA Oversight

Posted on digi By digi

In clinical trials, accurate and timely documentation of biospecimen collection, handling, and disposition is essential for compliance with Good Clinical Practice (GCP) guidelines. The FDA and EMA have repeatedly emphasized that inadequate or inconsistent sample documentation can lead to data integrity concerns, protocol deviations, and regulatory action.

Click to read the full article.

Laboratory and Sample Management, Sample Collection SOPs